Pierre Decazes
Pierre Decazes is an expert in Nuclear medicine at Centre Henri Becquerel (France). Pierre Decazes has authored 120 publications, the most recent in 2026, and is an investigator in 6 clinical trials, 3 of them ongoing. SLR score: 426 (community average: 125). How the SLR is computed.
LeadR Profile
Nuclear medicine
Subspecialties: Hematology - Oncology - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2014 - 2026
Number : 120
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Automatic lesion segmentation in ⁶⁸Ga-PSMA PET/CT and ¹⁷⁷Lu-PSMA SPECT/CT: added value of PET-guided SPECT in a bicentric study. PMID 42387196 — single photon emission computed tomography computed tomography, neoplasms, prostate, positron emission tomography computed tomography, neoplasm metastasis, tomography, emission-computed, single-photon, prostatic neoplasms, therapeutics | EJNMMI Res | 2026 | 0 |
| Predicting survival of patients treated with antibody-drug conjugates in early-phase clinical trials using AI-quantified 3D body composition on CT scans. PMID 42211497 — safety, pharmaceutical preparations, body composition, multivariate analysis, therapeutics, artificial intelligence, tissues, adipose tissue | Front Oncol | 2026 | 0 |
| Teaching Applied Artificial Intelligence in Health Schools: An Example from Rouen and Nice Universities in France. PMID 42175330 — medical informatics, intelligence, teaching, schools, artificial intelligence, universities | Stud Health Technol Inform | 2026 | 0 |
| Prognostic Value of Combined Baseline FDG PET/CT Radiomic Parameters in Primary Mediastinal B-Cell Lymphoma. PMID 42118857 — cells, lymphoma, b-cell, lymphoma, neoplasms, positron emission tomography computed tomography, tumor burden, risk factors, therapeutics, b-lymphocytes | Blood Adv | 2026 | 0 |
| Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study. PMID 41979332 — cells, circulating tumor dna, lymphoma, b-cell, lymphoma, neoplasms, predictive value of tests, therapeutics, dna, b-lymphocytes | Blood Adv | 2026 | 0 |
Clinical Studies 6
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
3 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Dynamic 68Ga PSMA and 18F FDG PET CT Analysis Prior to 177Lu PSMA NCT06450548 — neoplasms, adenocarcinoma, prostate, positron emission tomography computed tomography, liver, fluorodeoxyglucose f18, prostatic neoplasms, therapeutics | N/A | Recruiting | 2025 |
| Oxaliplatin Nivolumab in Combination With Trifluridine Tipiracil or 5 fluorouracile in Frail Patients With Advanced Recurrent or Metastatic Gastric Oesophageal or Gastroesophageal Junction Cancer NCT05476796 — leucovorin, trifluridine, esophagus, pharmaceutical preparations, esophagogastric junction, neoplasms, adenocarcinoma, disease progression, drug combinations, recycling, oxaliplatin, fluorouracil, neoplasm metastasis, nivolumab, therapeutics, capecitabine | Phase 2 | Active not recruiting | 2023 |
| A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide Doxorubicin Vincristine and Prednisone (CHOP) in Circulating Tumor (ct)DNA High Risk Patients With Untreated Diffuse Large B Cell Lymphoma NCT04980222 — cytokines, cells, body surface area, prednisolone, safety, prednisone, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, cyclophosphamide, doxorubicin, neoplasms, cytokine release syndrome, rituximab, vincristine, therapeutics, dna, b-lymphocytes | Phase 2 | Active not recruiting | 2022 |
LeadR Networks
Main global connection map